Compare AGNC Investment Corp (AGNC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Regeneron Pharmaceuticals Inc — how do they compare? AGNC Investment Corp trades at $10.9 (market cap $12.74B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.5× AGNC Investment Corp's market cap, and AGNC Investment Corp pays the higher dividend (13.4%). Which is the better fit depends on your goals.
| AGNC | REGN | |
|---|---|---|
Market Cap | $12.74B | $83.19B |
Sector | Financials | Health |
52-Week High | $12.17 | $812.27 |
52-Week Low | $9.46 | $555.51 |
Dividend Yield | 13.4% | 0.47% |
Enterprise Value | — | $77.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.84, up 2.17% today, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The stock offers a high dividend yield, with consistent monthly payouts, and trades at a P/E of 5.39 and P/B of 1.22. Recent news highlights its 13%+ yield and stable dividend history, though analyst consensus is mixed with a Hold majority.
Outlook remains positive due to robust net income margins above 94% and economic returns, but risks include interest rate sensitivity and leveraged mortgage securities. The consensus price target of $11.30 suggests modest upside, supported by institutional interest and earnings momentum, though volatility from macroeconomic factors warrants caution.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
